SPOTLIGHT: Synta gains $80M from GSK

The FTC has cleared GlaxoSmithKline's deal with Synta, paving the way for Synta to receive an $80 million dollar up-front payment. Back in October GSK and Synta inked a $1.1 billion deal for STA-4783, which has demonstrated efficacy in improving median survival rates for melanoma patients in a mid-stage study. Synta was a 2004 Fierce 15 company. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.